Ankit Mangla, Chanmi Lee, Matthew M Mirsky, Margaret Wang, Luke D Rothermel, Richard Hoehn, Jeremy S Bordeaux, Bryan T Carrol, Jason Theuner, Shawn Li, Pingfu Fu, John M Kirkwood
IMPORTANCE: Despite the clear potential benefits of neoadjuvant therapy, the optimal neoadjuvant regimen for patients with high-risk resectable melanoma (HRRM) is not known. OBJECTIVE: To compare the safety and efficacy of dual checkpoint inhibitors with anti-programmed cell death protein-1 (anti-PD1) therapy in a neoadjuvant setting among patients with HRRM. DESIGN, SETTING, AND PARTICIPANTS: In this pooled analysis of clinical trials, studies were selected provided they investigated immune checkpoint inhibitor treatment, were published between January 2018 and March 2023, and were phase 1, 2, or 3 clinical trials...
March 28, 2024: JAMA Oncology